The effect of cilostazol, a cyclic nucleotide phosphodiesterase III inhibitor, on heparin-binding EGF-like growth factor expression in macrophages and vascular smooth muscle cells.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Biochemical and Biophysical Research Communications - BBRC

• Publication date

  1997-09-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1006/BBRC.1997.7323PMID 9299535
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular Cloning: A Laboratory Manual

  2001cited by this paper
• Selective Induction of Heparin-binding Epidermal Growth Factor-like Growth Factor by Methylglyoxal and 3-Deoxyglucosone in Rat Aortic Smooth Muscle Cells

  1997cited by this paper
• Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases

  1997cited by this paper
• Ligands for ErbB-family receptors encoded by a neuregulin-like gene

  1997cited by this paper
• A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4.

  1997cited by this paper
• Topological Analysis of the Integral Membrane Protein, Type 1 Iodothyronine Deiodinase (D1) (*)

  1995cited by this paper
• Epiregulin

  1995cited by this paper
• Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques.

  1995cited by this paper
• Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells.

  1995cited by this paper
• T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells.

  1994cited by this paper
• Heparin-binding EGF-like growth factor synthesis by smooth muscle cells.

  1994cited by this paper
• Heparin-binding epidermal growth factor-like growth factor expression in cultured fetal human vascular smooth muscle cells. Induction of mRNA levels and secretion of active mitogen.

  1993cited by this paper
• Betacellulin: a mitogen from pancreatic beta cell tumors.

  1993cited by this paper
• Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate

  1993cited by this paper
• The pathogenesis of atherosclerosis: a perspective for the 1990s

  1993cited by this paper
• Heparin and dibutyryl cAMP modulate gene expression in stimulated human saphenous vein smooth muscle cells

  1993cited by this paper
• Effect of Cilostazol, a Cyclic AMP Phosphodiesterase Inhibitor, on the Proliferation of Rat Aortic Smooth Muscle Cells in Culture

  1992cited by this paper
• Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein.

  1992cited by this paper
• Tumor necrosis factor increases transcription of the heparin-binding epidermal growth factor-like growth factor gene in vascular endothelial cells.

  1992cited by this paper
• Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit.

  1992cited by this paper
• A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF

  1991cited by this paper
• Structure and function of human amphiregulin: a member of the epidermal growth factor family.

  1989cited by this paper
• Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

  1987cited by this paper
• In vitro vascular relaxation by new inotropic agents: relationship to phosphodiesterase inhibition and cyclic nucleotides.

  1987cited by this paper
• Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatography

  1984cited by this paper
• Positive inotropic agents.

  1984cited by this paper
• Human transforming growth factor-alpha: precursor structure and expression in E. coli.

  1984cited by this paper
• Human transforming growth factor-α: Precursor structure and expression in E. coli

  1984cited by this paper
• Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography.

  1984cited by this paper
• Functional angiotensin II receptors in cultured vascular smooth muscle cells

  1982cited by this paper
• Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.

  1979cited by this paper
• ISOLATION AND BIOLOGICAL EFFECTS OF AN EPIDERMAL GROWTH-STIMULATING PROTEIN.

  1964cited by this paper

• Exploration of the Role of Cilostazol in Brugada Syndrome: Mechanisms, Therapeutic Potential, and Implications in the Prevention of Ventricular Arrhythmias

  2026cites this paper
• Anti‐inflammatory properties of cilostazol: Its interruption of DNA binding activity of NF‐&kgr;B from the Toll‐like receptor signaling pathways

  2018cites this paper
• Die Wirkung des Phosphodiesterase-3-Inhibitors Cilostazol auf das Tumorwachstum von kolorektalen Lebermetastasen nach ausgedehnter Leberteilresektion

  2014cites this paper
• Cilostazol and primary-PCI: mirage or good alternative?

  2012cites this paper
• Cilostazol Versus Aspirin for Secondary Prevention of Vascular Events After Stroke of Arterial Origin

  2011cites this paper
• Heparin-binding epidermal growth factor expression in KATO-III cells after Helicobacter pylori stimulation under the influence of strychnos Nux vomica and Calendula officinalis

  2010cites this paper
• Cilostazol versus aspirin for secondary prevention of vascular events after stroke

  2009cites this paper
• Cilostazol attenuates MCP‐1 and MMP‐9 expression in vivo in LPS‐administrated balloon‐injured rabbit aorta and in vitro in LPS‐treated monocytic THP‐1 cells

  2008influential citation
• Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.

  2006cites this paper
• Bench to Bedside: Multiple Actions of the PDE3 Inhibitor Cilostazol

  2006cites this paper
• Profile of differentially expressed genes in blood vessels and blood cells of hyperlipidemia rats using suppression subtractive hybridization.

  2005cites this paper
• Comparison of cilostazol and ticlopidine coadministered with aspirin for long-term efficacy and safety after coronary stenting; a meta-analysis

  2005cites this paper
• Comparison of Cilostazol and Ticlopidine for One-Month Effectiveness and Safety after Elective Coronary Stenting

  2004cites this paper
• Cilostazol as a unique antithrombotic agent.

  2003cites this paper
• The pharmacology of cilostazol

  2002cites this paper
• Cilostazol: Treatment of Intermittent Claudication

  2001cites this paper
• Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation.

  2001cites this paper
• Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family.

  2001cites this paper
• Cyclic AMP inhibits agonist-induced heparin-binding EGF gene expression independently of effects on p42/p44 MAPK activation.

  2000cites this paper
• Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction.

  1999cites this paper
• Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery.

  1999cites this paper
• Effect of Cilostazol on Soluble Adhesion Molecules and Platelet-derived Microparticles in Patients with Diabetes

  1998cites this paper